August 12, 2008 - American HealthChoice Inc. (AMHI), a medical services company with medical clinics in Texas and Tennessee, said today the FDA approved its OmniBody Scan, an infrared thermal imaging camera that will be able to detect patterns of abnormality within the human body.
In conjunction with existing technologies, the OmniBody Scan will be able to identify problems early enough for prevention and treatment, according to the company.
"Our initial focus will be the worldwide problem of breast cancer,” said Pat McGlashan, president of RehabCo, a division of AMHI. “The dilemma that all women have is that having X-rays to detect breast cancer may cause breast cancer. The OmniBody Scan is a noninvasive tool that will have no harmful side effects. The earlier that breast cancer is detected equates to a much higher chance of survival, especially with Inflammatory Breast Cancer.”
The OmniBody Scan is manufactured specifically for American HealthChoice by an infrared imaging manufacturer. Efforts have begun to solicit resellers to penetrate the U.S. market with both the OmniBody Scan and the company's adjunct support system of providing high quality interpretations of the infrared images, said AMHI.
Five years ago, the U.S. Preventive Services Task Force, an independent panel of experts in primary care and prevention, examined data from numerous clinical trials and estimated that screening mammography every one or two years in women in their 40s resulted in a 15 percent decrease in breast cancer mortality after 14 years of follow-up. But, analyses also made note of the potential harm of screening, including radiation exposure, procedure- associated pain, false-positive results, over-diagnosis and potentially unnecessary treatment.
The OmniBody Scan, a noninvasive technology reportedly with no side effects, is available immediately.